Last reviewed · How we verify
NCT00786656
Community Cancer Centers Pilot Patient Survey
trial in Malignant Neoplasms in 3,955 participants. Completed in 11 May 2015.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,955 |
| Start date | 3 November 2008 |
| Estimated completion | 11 May 2015 |
| Sites | 1 location across United States |
Conditions studied
- Malignant Neoplasms — all drugs for Malignant Neoplasms →
- Cancer — all drugs for Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 21 to 99, any sex, with Malignant Neoplasms or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: * Studies suggest that cancer patients diagnosed and treated in a facility with multi-specialty care and clinical research may live longer and have a better quality of life than patients treated elsewhere. * The NCI Community Cancer Centers Pilot Program (NCCCP) is a 3-year program to test the concept of a national network of community cancer centers to expand cancer research and deliver the most advanced cancer care to Americans in their own communities. * The pilot program includes a survey of cancer patients receiving care at the pilot sites. Objectives: * To gain an understanding of the experiences of adult patients who receive services at the NCCCP pilot sites and assess if and how their experience changes over the study period. Data about the following are collected: * Patients information needs and awareness of the NCCCP program * Clinical trials experience * Access to health care * Perspectives on patient-provider communication * Experiences with patient navigation, self-management, medical decision-making and survivorship * Satisfaction with care and quality of life Eligibility: * Patients 21 years or older at the time of diagnosis * Treatment at the cancer center for at least 3 months since July 1, 2007 Design: * Participants complete a 25-minute questionnaire covering the care they received at their cancer center, their experience with making medical appointments and how long they waited to see the doctor. The survey includes information on the following: * Services at the cancer center * Getting needed care * Assistance for patients and their families * Communication with the cancer care team * Clinical trials * Care after finishing treatment * Evaluation of care * Health and medical history * Background information (demographics)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00786656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Neoplasms
Currently open trials in the same condition.
- NCT05538130 — A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So · Phase 1 · recruiting
- NCT05394428 — A Multi Center Study of Sexual Toxicities After Radiotherapy · recruiting
- NCT04660929 — CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting
- NCT00026884 — Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00786656 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 17 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00786656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing